Return to homepagePandemic Pact

Nabriva Therapeutics GMBH

  • Funded by Austrian Research Promotion Agency (FFG)
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    Austrian Research Promotion Agency (FFG)

  • Research Location

    Austria

  • Lead Research Institution

    Nabriva Therapeutics GMBH

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

In addition to potent antibacterial activity, pleuromutilins, and above all the antibiotic lefamulin (Xenleta ™), which is approved in the USA and approved in Europe, have antiviral and anti-inflammatory activity. The aim of the Lefamulin & COVID-19 project is to research lefamulin in these new indications. The successful establishment of antiviral and / or anti-inflammatory structure-activity models within the pleuromutilins opens up new ways to develop new therapies for viral diseases such as COVID-19.